Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
In this report we present a 37-year-old thalassemia patient with hyperferritinemia referred to our Microcytemia Centerat the beginning of deferasirox (DFX) therapy. Treatment with subcutaneous infusions of desferrioxamine (DFO) had started when he was 10 years old. During the 6-month DFX treatment, serum ferritin levels progressively increased from 600 to 2,700 ng/ml despite progressive DFX dose adjustments.This paradoxically abnormal ferritin levels required drug discontinuation but were not paralleled by a similar iron burden in T2 * magnetic resonance imaging. In this clinical case, ferritin levels were inappropriately increased following initiation of DFX treatment, but in the presence of an almost unmodified pattern of organ iron overload. Excluding the diagnostic dilemma of an improbable failure of DFX chelation, the pathogenesis of this phenomenon remains to be clarified, thus further complicating the problem of ferritin specificity and its role in monitoring chelation efficacy and in adapting DFX dosage in a limited period of treatment.
Ricchi
Paolo
P
Oncohematologic Department, Microcytemia Center A. Mastrobuoni, A. Cardarelli Hospital, Italy. paolo.ricchi@ospedalecardarelli.it
Ammirabile
Massimiliano
M
Spasiano
Anna
A
Costantini
Silvia
S
Cinque
Patrizia
P
Di Matola
Tiziana
T
Prossomariti
Luciano
L
D000328:Adult; D001565:Benzoates / Q000009:adverse effects*; D015913:Chelation Therapy / Q000009:adverse effects*; D000077588:Deferasirox; D005293:Ferritins / Q000097:blood*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D014230:Triazoles / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000150:complications / Q000188:drug therapy*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D005293:Ferritins; D000077588:Deferasirox